Menu
No results found.
Weekly Share Price & Valuation Overview
Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Debt-to-equity >2 — elevated leverage may constrain flexibility.
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 3.08B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 24.01B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 9.86B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 6.97B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 3.11B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 26.68
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.26
- Shares Outstanding
- 369.79M
- Float Shares
- 225.67M
- Implied Shares Outstanding
- 371.61M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
18.02%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
31.55%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
70.70%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
0.99%
- ROA Return on assets: net income ÷ total assets.
-
4.35%
- Revenue Growth Year-over-year revenue growth.
-
5.30%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
13.68%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
13.80%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.79
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 14787.75
- Total Cash Cash and equivalents.
- USD 1.73B
- Total Debt Short + long-term interest-bearing debt.
- USD 21.74B
- Net Debt Total debt − cash (negative = net cash).
- USD 20.01B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 6.99
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 1.51B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 1.35B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
15.28%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
13.66%
- Cash Conversion (OpCF/EBITDA)
- 0.48
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.